



NOTICE OF MATERIAL EVENT

BREAKTHROUGH CHEMISTRY INC.

8891 Brighton Lane, Suite 108

Bonita Springs, FL 34135

www.breakthroughchemistry.com

Tel: 1-800-549-6970

Email: IR@breakthroughchemistry.com

BONITA SPRINGS, FL, March 11, 2026 / (OTCPINK: BKTH) — Breakthrough Chemistry Inc. (“BKTH” or the “Company”), a Nevada corporation headquartered in Bonita Springs, Florida, announces Formal Closure of MedeSol Relationship and Confirmation of Independent Licensing Structure and GS Capital Blends LLC (GSCB) BKTH Patent & Formulation License Confirmation Letter

Material Event: Formal Closure of MedeSol Relationship and Confirmation of Independent Licensing Structure

Breakthrough Chemistry Inc. (“BKTH”) provides this Material Event disclosure to formally document the status of its historical agreements with MedeSol Global Inc. (“MedeSol”), to clarify the Company’s response to MedeSol’s prior correspondence, and to confirm BKTH’s current intellectual property and licensing position as it enters FY2026.

1. MedeSol’s July 9, 2025 Termination Notice

On July 9, 2025, MedeSol issued a document titled “Notice of Noncompliance – Formal Acknowledgment of Termination and Revocation of IP Access.”

In that notice, MedeSol stated that:

- the January 31, 2025 Consolidated Amendment Agreement and all related agreements were terminated,
- BKTH (then operating under Megola, Inc.) no longer held any rights or licenses to MedeSol’s intellectual property,
- all contractual relationships between the parties had ended,
- only confidentiality obligations survived.

BKTH acknowledged receipt of this notice but did not accept MedeSol's legal characterizations, as the January 31 Agreement required Nevada arbitration for any termination to be valid. MedeSol did not initiate arbitration.

2. MedeSol's December 31, 2025 Confirmation of Termination

On December 31, 2025, MedeSol's General Counsel, Thomas Gehl, reaffirmed in writing that:

- "Any and all contractual relationships between MedeSol Global Inc. and Breakthrough Chemistry Inc. have terminated,"
- including the January 31, 2025 Agreement and the February 9, 2025 Royalty Credit and Inventory Agreement,
- and that BKTH held no ongoing license rights under those agreements.

This communication was addressed to BKTH's corporate email and copied to MedeSol's senior management.

3. BKTH's Position at the Time

At the time of MedeSol's termination declarations, BKTH disputed MedeSol's unilateral termination because:

- the January 31 Agreement required binding Nevada arbitration,
- MedeSol had not provided required BOMs, formulations, or patent documentation,
- BKTH was still evaluating the status and validity of MedeSol's claimed patent filings.

BKTH reserved all rights and did not concede MedeSol's assertions.

No arbitration was ever initiated by MedeSol.

4. BKTH's Current IP and Licensing Position (2025–2026)

Between Q3 2025 and Q1 2026, GS Capital Blends LLC ("GSCB") completed and filed eight (8) independent patent applications covering proprietary oxidative media, treated mineral blends, and coating technologies.

Key facts:

- GSCB is the owner and applicant of all eight patent filings.
- BKTH holds global commercialization and exploitation rights to these technologies under the existing licensing structure previously executed between GSCB and BKTH.

- These patents and formulations are independent of MedeSol's intellectual property and do not rely upon, derive from, or infringe any MedeSol filings referenced in prior agreements.
- BKTH's Board of Directors will determine any future royalty or license-fee obligations payable to GSCB in accordance with the existing licensing framework and future negotiated agreements.

As a result, BKTH's product lines, formulations, and commercialization activities are now based solely on technologies licensed from GSCB.

BKTH no longer relies on any MedeSol intellectual property, formulations, or representations.

5. Final Correspondence Sent to MedeSol (March 2026)

On **March 8, 2026**, BKTH issued a final communication to MedeSol's corporate management acknowledging:

- MedeSol's longstanding position that all agreements were terminated (as stated in the December 31, 2025 email),
- BKTH's independent operations since that date,
- BKTH's development and licensing of its own technology through GSCB,
- BKTH's lack of reliance on any MedeSol IP,
- and BKTH's intention to move forward with no further interaction or dependency.

BKTH expressly reserved all rights and made no admissions regarding MedeSol's prior claims.

This correspondence formally closes the relationship.

6. Impact on BKTH's Operations

BKTH confirms:

- There are no remaining operational, financial, or licensing obligations between BKTH and MedeSol.
- BKTH's technology platform is now fully independent through its licensing arrangement with GSCB.
- No arbitration, litigation, or outstanding disputes remain active between the parties.
- BKTH's disclosures, product offerings, and commercialization plans are now based solely on GSCB-owned intellectual property licensed to BKTH.

7. Forward-Looking Position

BKTH enters FY2026 with:

- a fully independent technology platform,
- a clean chain-of-title for all formulations and patents it commercializes,
- no reliance on MedeSol's intellectual property,
- and a clear licensing structure under which the BKTH Board will determine any future royalty flows to GSCB.

This disclosure is made to ensure transparency and to update prior public statements in accordance with OTC Markets guidelines.

GSCB BKTH Patent & Formulation License Confirmation Letter

GS Capital Blends LLC

23160 Fashion Dr, Suite 250B, Estero, FL, 33928

To:

Board of Directors

Breakthrough Chemistry Inc. (BKTH)

8891 Brighton Lane, Suite 108, Bonita Springs, FL, 34135

Re: Confirmation of Patent Ownership, Formulation Development, and Licensing Rights Granted to Breakthrough Chemistry Inc.

To the Board of Directors:

GS Capital Blends LLC ("GSCB") issues this letter to formally confirm the ownership, development history, and licensing structure governing the formulations and intellectual property currently utilized by Breakthrough Chemistry Inc. ("BKTH").

1. Ownership of Intellectual Property and Patent Filings

GSCB is the sole owner of the following intellectual property:

- All formulations, blends, and chemical processes developed by GSCB since 2019
- All improvements, enhancements, and derivative works created by GSCB
- All eight (8) patent applications filed by GSCB between BKTH's Q3 2025 and Q1 2026

These patents cover proprietary oxidative media, treated mineral blends, and coating technologies developed exclusively by GSCB.

None of these filings rely upon, derive from, or incorporate any intellectual property previously associated with MedeSol Global Inc.

2. Development of Formulations and Blends

GSCB confirms that:

- It independently developed the formulations and blends currently commercialized by BKTH
- These formulations represent advancements beyond earlier recipes
- GSCB performed the R&D, optimization, and patent-level refinement
- GSCB retains ownership of all resulting intellectual property

3. Licensing Rights Granted to BKTH

Under the existing licensing structure previously executed between GSCB and BKTH:

- BKTH holds global commercialization and exploitation rights to all GSCB formulations and patent filings
- BKTH is authorized to manufacture, market, distribute, and sell products based on these formulations
- BKTH may sublicense manufacturing to approved toll blenders
- BKTH may incorporate these technologies into its product lines without restriction

This license remains in full force and effect.

4. Royalty and License-Fee Determination

Consistent with the existing licensing framework:

- Any future royalties or license fees payable by BKTH to GSCB
- Will be determined solely by the Board of Directors of BKTH
- As part of future negotiated product, patent, or commercialization agreements
- GSCB may initially charge a one-time joint patent fees to BKTH for prior approval

GSCB acknowledges and agrees to this governance structure.

5. Confirmation of Rights

GSCB hereby confirms that BKTH:

- Holds full global rights to commercialize all GSCB-owned formulations and patents
- Is authorized to continue all operations based on these technologies
- Is not restricted by any third-party claims relating to these formulations or patents

This confirmation is issued for BKTH's internal records, auditors, regulatory filings, and investor disclosures.

ABOUT BREAKTHROUGH CHEMISTRY INC.

Breakthrough Chemistry, Inc. is a Nevada Corporation with its corporate office in Bonita Springs, FL and traded under the symbol BKTH on the OTCID Market. Breakthrough Chemistry develops clean, engineered chemistry platforms designed to replace outdated, toxic, and increasingly regulated legacy chemistries. Our technologies are PFAS-free, non-volatile, non-migrating, and water-compatible, delivering measurable performance across global industrial and consumer sectors. The company's portfolio includes eight patents pending across three master platforms: • Stabilized Halogen — rechargeable oxidative chemistry for odor destruction, VOC reduction, antimicrobial protection, and food safety. • SiO₂ Surface Protection — ultra-thin, durable silica micro-layers that enhance clarity, repel water, resist fouling, and strengthen surfaces across transportation, marine, eyewear, agricultural, and PFAS-free packaging applications. • Fire-Inhibitor Systems — water-based fire-inhibitor sprays for textiles, wood, carpets, foam, and flexible materials, paired with mineral-anchored systems integrated into plastics, composites, insulation, and building materials for material-level flame resistance. BKTH operates a flexible, scalable business model built on global licensing, OEM fee structures, regional toll blending, and chemistry supply. This approach enables local manufacturing, consistent global performance, and straightforward adoption across multiple verticals.

Breakthrough Chemistry Inc.
www.breakthroughchemistry.com
IR@breakthroughchemistry.com
<https://x.com/megolacorp>
1-800-549-6970

Stock information: <https://www.otcmartets.com/stock/BKTH/profile>